Litcius/Paper detail

1757O Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients

Alexander N. Shoushtari, Laura Collins, Enrique Espinosa, Himanshu Sethi, Sarah Stanhope, Shaad E. Abdullah, Alexandra P. Ikeguchi, K. Ranade, Omid Hamid

2021Annals of Oncology20 citationsDOI

Topics & Concepts

MedicineSurrogate endpointOncologyMetastatic melanomaResponse Evaluation Criteria in Solid TumorsMelanomaClinical endpointInternal medicineCancer researchClinical trialChemotherapyProgressive diseaseOcular Oncology and TreatmentsProtein Degradation and InhibitorsImmunotherapy and Immune Responses
1757O Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients | Litcius